Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study

Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study

Objective: The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) still protracts worldwide. HFB30132A is an anti- SARS-CoV-2 monoclonal antibody purposely engineered for an extended half-life with neutralizing activity against majo...

Full description

Bibliographic Details
Main Authors: Shanshan Li, Xiaojie Wu, Nanyang Li, Guoying Cao, Jingjing Wang, Yuancheng Chen, Size Li, Jinjie He, Jufang Wu, Haijing Yang, Ke Lin, Chao Qiu, Angela Liu, He Zhou, Francisco Adrian, Liang Schweizer, Wenhong Zhang, Jingwen Gu, Jing Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Pharmacology
Subjects:
neutralizing antibody
monoclonal antibody
SARS-CoV-2
HFB30132A
COVID-19
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1117293/full

Similar Items

Similar Items